The Journal of dermatological treatment · 2025
Spesolimab for a child with generalized pustular psoriasis accompanied epilepsy and hyperactivity.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yudan, Qin Jie, Peng Li, He Linli, Yang Beichen, Yang Mei, Feng Yanyan
Аннотация
OBJECTIVES: To evaluate the therapeutic efficacy and safety of spesolimab in pediatric GPP treatment.
METHODS: We report a 10-year-old male pediatric patient with refractory Generalized Pustular Psoriasis (GPP), comorbid epilepsy, hyperactivity, hypoproteinaemia. The coexistence of IL36RN: c.115 + 6T > C homozygous mutation and c.227C > T(p.P76L) heterozygous variation may have worsened his disease phenotype.
RESULTS: Spesolimab treatment achieved a complete and rapid response. Pustules, erythema, and scales cleared within a week.
CONCLUSIONS: Spesolimab is effective in treating pediatric GPP patients, and it is potential to be a clinical treatment strategy for pediatric GPP in the future.
METHODS: We report a 10-year-old male pediatric patient with refractory Generalized Pustular Psoriasis (GPP), comorbid epilepsy, hyperactivity, hypoproteinaemia. The coexistence of IL36RN: c.115 + 6T > C homozygous mutation and c.227C > T(p.P76L) heterozygous variation may have worsened his disease phenotype.
RESULTS: Spesolimab treatment achieved a complete and rapid response. Pustules, erythema, and scales cleared within a week.
CONCLUSIONS: Spesolimab is effective in treating pediatric GPP patients, and it is potential to be a clinical treatment strategy for pediatric GPP in the future.